A method and screening model for screening small molecule inhibitors of the main protease of the new coronavirus
The high-throughput screening model established through the principles of E. coli prokaryotic expression and fluorescence polarization has solved the problem of high false positive rate and complicated operation of the screening method of primary protease of the new coronavirus, and achieved rapid, sensitive and economical high-throughput Screening, suitable for drug screening for the new coronavirus and other pathogenic viruses.
Patent Information
- Application Number
- CN202110747923.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-07-01
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2041-07-01
AI Technical Summary
The existing screening method for the main protease of the new coronavirus has the disadvantages of high false positive rate, high screening cost, cumbersome operation, poor stability, and long screening cycle, which limits its application in large-scale high-throughput screening.
The highly active Mpro recombinant protein was prepared by E. coli prokaryotic expression method, and the hydrolysis reaction with FITC-S-Biotin and avidin-terminated hydrolysis reaction was established through the principle of fluorescence polarization, combined with a multifunctional microplate reader to detect mP value, and a fluorescence polarization high was established. Throughput screening model, used to screen for small molecule inhibitors of the main protease of the new coronavirus.
This method achieves fast, sensitive and economical high-throughput screening, suitable for rapid screening and activity evaluation of anti-CoV drugs. It has the advantages of homogeneous reaction, easy operation and low cost, and can be used for other pathogenic viruses. Rapid screening of key protease small molecule inhibitors.
Smart Images

Figure CN113699212B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of pharmaceutical biotechnology, and specifically, relates to a method and a screening model for screening small molecule inhibitors of the main protease of the new coronavirus. Background Art
[0002] The rapid development of novel coronavirus (SARS-CoV-2) vaccines, humanized antibodies, and anti-COVID-19 drugs has become a major scientific issue facing the scientific community. Although significant progress has been made in the development of COVID-19 vaccines, safe and effective broad-spectrum anti-COVID-19 drugs are also crucial for unvaccinated individuals or situations where high-frequency genetic mutations of the virus lead to reduced vaccine protection (Wang Z, et al. Nature, 2021). Although some candidate antiviral drugs have been used in clinical treatment, such as remdesivir, favipiravir, ribavirin, and telbivudine, they have shown limited or no efficacy in large-scale clinical trials. It is of great significance to actively develop new broad-spectrum anti-COVID-19 drugs.
[0003] Current studies have shown that the evolutionarily highly conserved main protease (Mpro) of the new coronavirus has an important biological function in regulating the replication of the new coronavirus RNA, and the human body lacks a homologous protease, which has become one of the ideal targets for the development of new broad-spectrum anti-coronavirus drugs (Morse JS, et al. Chembiochem, 2020; Jin Z, et al. Nature, 2020; Jin Z, et al. Biochem Biophys Res Commun, 2021). In the development of highly selective small molecule inhibitors of the new coronavirus Mpro, the establishment of a simple, rapid, sensitive and economical high-throughput drug screening model is an important foundation and key technology for its efficient screening and development (Qi Haiyan, et al. Chemistry of Life, 2021). The currently reported screening methods for Mpro small molecule inhibitors mainly include virtual screening, fluorescence resonance energy transfer (FRET), luciferase reporter gene screening, green fluorescent protein shear complementation and phenotypic screening (Li Z, et al. Proc Natl Acad Sci USA, 2020; Zhu W, et al. ACS Pharmacol Transl Sci, 2020; Coelho C, et al. PLoS One, 2020; Hung HC, et al. Antimicrob Agents Chemother, 2020; Ma Ling, et al. Acta Pharmaceutica Sinica, 2020; Rawson J, et al. Viruses, 2021; Froggatt HM, et al. J Virol, 2020; Rothan HA, et al. Mol Biotechnol, 2021; Riva L, et al. Nature, 2020). However, the above screening methods generally have disadvantages such as high false positive rate, high screening cost, cumbersome operation, poor stability, and long screening cycle, which greatly limit their application in large-scale high-throughput screening (Qi Haiyan, et al. Chemistry of Life, 2021). Therefore, it is of great significance to actively develop a simple, rapid, sensitive, and economical new high-throughput screening model for Mpro small molecule inhibitors. Summary of the invention
[0004] The present invention first relates to a method for screening small molecule inhibitors of the main protease of the new coronavirus, wherein the method comprises the following steps:
[0005] (1) Prepare highly active Mpro recombinant protein using the Escherichia coli prokaryotic expression method.
[0006] (2) Add the compound to be screened and incubate it with the Mpro recombinant protein.
[0007] Preferably, the Mpro recombinant protein solution (the concentration of the Mpro recombinant protein is 100 to 2000 nM) and the compound to be screened (the concentration is 1 to 5 mM) are mixed in proportion and incubated together at room temperature for 20 to 60 minutes.
[0008] More preferably, the Mpro recombinant protein solution (the concentration of the Mpro recombinant protein is 400 nM) and the compound to be screened (the concentration is 3 mM) are mixed in a ratio of 1:29 (v / v), and then incubated together at room temperature for 40 min.
[0009] (3) Use fluorescein isothiocyanate (FITC) and FITC-Substrate-Biotin peptide labeled with Biotin (FITC-S-Biotin: FITC-AVLQSGFRKK-Biotin) as Mpro hydrolysis substrates and incubate them at room temperature for 5 to 60 minutes.
[0010] Preferably, the concentration of FITC-S-Biotin is 20 to 100 nM, and the volume of the added FITC-S-Biotin solution is 1 / 2 to 1 / 1 (v / v) of the system in step (2). After adding FITC-S-Biotin, incubate at room temperature for 5 to 40 minutes.
[0011] More preferably, the concentration of FITC-S-Biotin is 60 nM, and the volume of the added FITC-S-Biotin solution is 2 / 3 (v / v) of the system in step (2). After adding FITC-S-Biotin, incubate at room temperature for 20 min.
[0012] (4) Terminate the hydrolysis reaction with avidin, incubate the mixture at room temperature for 1 to 30 min, and detect the mP value using a multifunctional microplate reader.
[0013] Preferably, the concentration of avidin is 10-500 nM, and the volume of the added avidin solution is 1 / 6-1 / 1 (v / v) of the system in step (2). After adding avidin, incubate at room temperature for 1-10 min, and detect the mP value with a multifunctional microplate reader.
[0014] More preferably, the concentration of avidin is 300 nM, and the volume of the avidin solution added is 1 / 3 (v / v) of the system in step (2). After adding avidin, incubate at room temperature for 5 minutes, and detect the mP value with a multifunctional microplate reader.
[0015] (5) Draw the inhibition curve of the target compound and calculate the IC of the target compound against the main protease of the new coronavirus50 value.
[0016] The method for preparing highly active Mpro recombinant protein by the E. coli prokaryotic expression method described in step (1) is:
[0017] ① Connect the codon-optimized Mpro gene to the pET-21a(+) expression vector to construct the recombinant plasmid Mpro-pET-21a;
[0018] ②Then transform the recombinant plasmid into E.coli Rosetta (DE3) competent cells for soluble expression of Mpro, and separate and purify the SARS-CoV-2 Mpro recombinant protein using a HisTrap affinity chromatography column.
[0019] In the step of drawing the inhibition curve of the target compound in step (5), the calculation formula of the inhibition rate is as follows:
[0020]
[0021] The present invention also relates to a fluorescence polarization screening kit for screening small molecule inhibitors of the main protease of the new coronavirus, wherein the kit comprises:
[0022] (1) Detect effective amounts of SARS-CoV-2 Mpro recombinant protein, fluorescent probe FITC-S-Biotin, and avidin;
[0023] (2) Necessary solvents and reagents.
[0024] The present invention also relates to the use of the fluorescence polarization screening kit for screening small molecule inhibitors of the main protease of the new coronavirus in screening small molecule inhibitors of the main protease of the new coronavirus.
[0025] The beneficial effects of the present invention are as follows:
[0026] The present invention discloses a fluorescence polarization high-throughput screening model for screening small molecule inhibitors of the main protease of the new coronavirus and a method for using the same, which belongs to the field of pharmaceutical biotechnology. The high-throughput screening model is based on the principle of fluorescence polarization, using the fluorescent probe FITC-S-Biotin as the hydrolysis substrate of the new coronavirus Mpro, and then using avidin to terminate its hydrolysis reaction, and using a multifunctional microplate reader to detect the mP value of the experimental system. Active compounds show higher mP values in this screening model, while inactive compounds show lower mP values. Specifically including:
[0027] (1) The fluorescence polarization high-throughput screening model established in the present invention is suitable for the rapid screening, discovery and activity evaluation of anti-new coronavirus drugs targeting the main protease;
[0028] (2) The fluorescence polarization high-throughput screening model established in the present invention has the advantages of homogeneous reaction, simple operation, sensitive detection, and low cost;
[0029] (3) The fluorescence polarization high-throughput screening model established by the present invention is not limited to the high-throughput screening of small molecule inhibitors of the main protease of the new coronavirus. Small molecule inhibitors of key proteases that regulate viral replication in other pathogenic viruses can also be applied or improved by the present invention for rapid screening and discovery. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 , the codon-optimized sequence and amino acid sequence of the SARS-CoV-2 Mpro recombinant protein in Example 1 of the present invention.
[0031] Figure 2 , Prokaryotic expression, separation and purification, and identification of biological activity of the new coronavirus Mpro recombinant protein in Examples 1 and 2 of the present invention. 2A, Prokaryotic expression and separation and purification of the new coronavirus Mpro recombinant protein: Lane M: protein standard molecular weight; Lane 1: bacterial protein; Lane 2: lysis supernatant; Lane 3: crude extract; Lane 4: purified Mpro recombinant protein. 2B: Standard curve of fluorescence intensity of MCA standard; 2C: Fluorescence intensity curve of Mpro recombinant protein of different concentrations after hydrolysis of MCA substrate.
[0032] Figure 3 , the reaction curve of the SARS-CoV-2 Mpro recombinant protein hydrolyzing the FITC-S-Biotin substrate in Example 3 of the present invention.
[0033] Figure 4 , the dose-effect curve and IC of GC-376 in the fluorescence polarization high-throughput screening model in Example 4 of the present invention 50 value.
[0034] Figure 5 , the Z factor value of the fluorescence polarization high-throughput screening model in Example 5 of the present invention.
[0035] Figure 6 , the dose-effect curve and IC of anacardic acid and ginkgolic acid in the fluorescence polarization high-throughput screening model in Example 6 of the present invention 50 value. DETAILED DESCRIPTION
[0036] Unless otherwise specified, the technical means used in the implementation are conventional biochemical methods well known to those skilled in the art, and the reagents and materials used can be obtained from commercial channels.
[0037] Example 1. Prokaryotic expression and purification of the novel coronavirus Mpro recombinant protein
[0038] Using Escherichia coli prokaryotic expression technology, the codon-optimized Mpro gene ( Figure 1 ) was connected to the pET-21a(+) expression vector to construct the recombinant plasmid Mpro-pET-21a. The recombinant plasmid was then transformed into E. coli Rosetta (DE3) competent cells, and the recombinants were screened for ampicillin resistance. The recombinants were inoculated into 1 liter of LB liquid culture medium (containing 100μg / mL ampicillin), cultured at 37°C for 7h, 0.2mM IPTG was added, and induced at 30°C for 8h. After the bacteria were disrupted by ultrasound, the lysis supernatant was separated and purified by HisTrap affinity chromatography column. The purified Mpro had an apparent molecular weight of 34kDa, with only one formylmethionine remaining at its amino terminus and a polyhistidine tag fused to its carboxyl terminus. The electrophoretic purity was greater than 90%, and the concentration was 3mg / mL( Figure 1 , Figure 2 A).
[0039] The codon-optimized Mpro gene sequence is shown in SEQ ID NO. 1, and the restriction sites used are NdeⅠ (CATATG) and XhoⅠ (CTCGAG). The amino terminus of the Mpro recombinant protein contains a formylmethionine (fMet) and the carboxyl terminus contains a polyhistidine tag.
[0040] SEQ ID NO.1:
[0041] CATATGAGTGGCTTTCGTAAAATGGCCTTTCCGAGCGGCAAAGTTGAAGGTTGTATGGTGCAGGTGACCTGCGGTACCACCACCCTGAATGGTCTGTGGCTGGATGATGTGGTTTATTGCCCGCGTCATGTGATTTGTACCAGTGAAGATATGCTGAATCCGAATTATGAAGATCTGCTGATTCGCAAAAGCAATCATAATTTTCTGGTGCAGGCCGGCAATGTTCAGCTGCGCGTGATTGGCCATAGTATGCAGAATTGCGTTCTGAAACTGAAAGTGGATACCGCAAATCCGAAAACCCCGAAATATAAATTTGTTCGCATTCAGCCGGGTCAGACCTTTAGCGTGCTGGCATGTTATAATGGTAGTCCGAGCGGTGTGTATCAGTGCGCAATGCGTCCGAATTTTACCATTAAGGGCAGTTTTCTGAATGGTAGCTGCGGCAGCGTTGGTTTTAATATTGATTATGATTGCGTGAGTTTCTGCTATATGCATCACATGGAACTGCCGACCGGTGTGCATGCAGGCACCGATCTGGAAGGTAATTTTTATGGCCCGTTTGTGGATCGCCAGACCGCACAGGCAGCCGGTACCGATACCACCATTACCGTTAATGTTCTGGCATGGCTGTATGCAGCCGTTATTAATGGTGACCGTTGGTTTCTGAATCGTTTTACCACCACCTTAAATGATTTTAATCTGGTTGCCATGAAGTATAATTACGAACCGCTGACCCAGGATCATGTGGATATTCTGGGCCCGCTGAGTGCCCAGACCGGTATTGCAGTTCTGGATATGTGTGCAAGCCTGAAAGAACTGCTGCAGAATGGTATGAATGGTCGTACCATTCTGGGTAGTGCACTGCTGGAAGATGAATTCACTCCGTTTGATGTTGTGCGCCAGTGTAGCGGTGTGACCTTTCAG CTCGAG
[0042] The encoded amino acid sequence is shown in SEQ ID NO.2,
[0043] SEQ ID NO.2:
[0044] MSGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDVVYCPRHVICTSEDMLNPNYEDLLIRKSNHNFLVQAGNVQLRVIGHSMQNCVLKLKVDTANPKTPKYKFVRIQPGQTFSVLACYNGSPSGVYQCAMRPNFTIKGSFLNGSCGSVGFNIDYDC VSFCYMHHMELPTGVHAGTDLEGNFYGPFVDRQTAQAAGTDTTITVNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYEPLTQDHVDILGPLSAQTGIAVLDMCASLKELLQNGMNGRTILGSALLEDEFTPFDVVRQCSGVTFQLEHHHHHH
[0045] Example 2. Identification of the biological activity of the SARS-CoV-2 Mpro recombinant protein
[0046] 1. Dilute 10μM MCA (7-methoxycoumarin-4-acetic acid, MCA) in TBS solution (50mM Tris, 150mM NaCl pH8.0) by 2-fold dilution to 5 concentration gradients, and use the wells containing only TBS solution as negative control wells. Add the above MCA dilution solution to a 384-well plate at 50μL / well. The total amount of MCA in each well is 0, 31.25, 62.5, 125, 250, and 500pmol, respectively. Set the automatic gain mode and use a multifunctional microplate reader to detect the relative fluorescence intensity value (relative fluorescence unit, RFU). According to the total amount of MCA in each well and the ΔRFU value (ΔRFU = RFU MCA -RFU0) to fit the regression equation and draw the MCA fluorescence intensity standard curve ( Figure 2 B).
[0047] 2. Dilute 2mM MCA-Substrate (MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2) to 10μM with TBS solution, and add Mpro to make the final concentrations 0, 0.25, 0.5, and 1μM, respectively. Add the above reaction solution to a 384-well plate at 50μL / well, set the gain value to 58, the detection temperature to 25°C, the excitation light to 320nm, the emission light to 405nm, the detection interval to 1s, the total detection time to 3min, and detect the RFU value with a multifunctional microplate reader. During the 30s hydrolysis reaction time, the RFU values at the T1 and T2 time points were recorded as RFU, respectively. T1 and RFU T2 , calculate ΔRFU=RFU T2 -RFU T1 ,pass Figure 2 The standard curve of B is used to calculate the total amount of MCA-AVLQ (pmol) produced by the hydrolysis of MCA-Substrate by Mpro within the time ΔT = T2-T1. The definition of activity unit (U) is: the amount of enzyme required for Mpro to hydrolyze MCA-Substrate to generate 1 pmol of MCA-AVLQ (product, P) per minute in the hydrolysis reaction at 25°C and pH 8.0.
[0048]
[0049] Using formula 2, the specific activity of purified Mpro is calculated to be no less than 50 000 U / mg ( Figure 2 C).
[0050] Example 3. Hydrolysis of FITC-S-Biotin Substrate by SARS-CoV-2 Mpro Recombinant Protein
[0051] 2mM FITC-S-Biotin was diluted to 60nM with fluorescence polarization reaction solution (10mM Tris, 50mM NaCl, 1mM DTTpH8.0), added to a 384-well plate at 20μL / well, and then 0, 25, 50, 100, 150, 175, 200, 300, 400, 500, 600, and 700nM Mpro were added in sequence, 30μL per well, and 3 sets of replicate wells were set up for each group. The plates were incubated at room temperature for 20min, and then 300nM avidin reaction solution was added at 10μL / well. The plates were incubated at room temperature in the dark for 5min, and the mP value was detected with a multifunctional microplate reader.
[0052] The Mpro hydrolysis reaction curve shows that 200 nM Mpro can fully hydrolyze the FITC-S-Biotin substrate to the product FITC-AVLQ ( Figure 3 ).
[0053] Example 4. Inhibitory activity of GC-376 in a fluorescence polarization high-throughput screening model
[0054] GC-376 is a small molecule inhibitor of SARS-CoV-2 Mpro that has been reported to have excellent activity ( Figure 4 A). 10mM GC-376 was diluted 2-fold with 400nM Mpro (starting concentration 2μM, 8 dilutions in total), added to a 384-well plate, 30μL per well, 3 sets of duplicate wells per group, and incubated at room temperature for 40min. Then 60nM FITC-S-Biotin was added to the 384-well plate in sequence, 20μL per well, and incubated at room temperature in the dark for 20min. Then 300nM avidin reaction solution was added at 10μL / well, and incubated at room temperature for 5min, and mP value was detected with a multifunctional microplate reader.
[0055] The negative wells were set as Mpro (400 nM, 29 μL / well) + DMSO (1 μL / well) + FITC-S-Biotin (60 nM, 20 μL / well) + avidin (300 nM, 10 μL / well), and the positive wells were set as fluorescence polarization reaction solution (29 μL / well) + DMSO (1 μL / well) + FITC-S-Biotin (60 nM, 20 μL / well) + avidin (300 nM, 10 μL / well). The inhibition curve of GC-376 was fitted and its IC was calculated. 50 value.
[0056]
[0057] Using Equation 3, calculate the IC of GC-376 in the fluorescence polarization screening model 50 The value is 0.127μM ( Figure 4 B), compared with the reported IC in the FRET screening model 50 The values are basically consistent (Vuong W, et al. Nat Commun, 2020), which shows that the established fluorescence polarization high-throughput screening model has good specificity.
[0058] Example 5. Z-factor values for fluorescence polarization high-throughput screening model
[0059] The Z factor is a core parameter for evaluating the stability of a drug high-throughput screening model. Using a multifunctional microplate reader, the Z factor of this fluorescence polarization high-throughput screening model was calculated to be 0.85, which meets the basic requirement that the Z factor in the high-throughput screening model is greater than 0.5 ( Figure 5 ).
[0060] Example 6. Method for using the fluorescence polarization high-throughput screening model
[0061] The initial screening concentration of the compound library was 1 mg / mL. 1 μL of the compound and 400 nM Mpro (29 μL / well) were added to a 384-well plate. After incubation at room temperature for 40 minutes, 60 nM FITC-S-Biotin was added, 20 μL per well, incubated at room temperature for 20 minutes, and then 300 nM avidin (10 μL / well) was added and incubated at room temperature for 5 minutes. At the same time, a negative control group (DMSO well) and a positive control group (GC-376 well, 1 μM) were set up, and the mP value was detected by a multifunctional microplate reader. The natural product compound library was high-throughput screened using the established fluorescence polarization high-throughput screening model, and anacardic acid (AA) and ginkgolic acid (GA) were successfully screened for good inhibitory activity. The IC 50 The values were 9.62 and 7.15 μM ( Figure 6 A, 6B). At present, studies have confirmed that anacardic acid and ginkgo biloba acid are small molecule inhibitors of SARS-CoV-2 Mpro and have good antiviral activity against SARS-CoV-2 (Xiong Y, et al. Fitoterapia, 2021; Chen Z, et al. Cell Biosci, 2021). This also shows that this fluorescence polarization high-throughput screening model has good practicality and promotion.
[0062] Although, the present invention has been described in detail with general description and specific embodiments thereof above, it is obvious that those skilled in the art can still make further improvements or modifications thereto on the basis of the present invention. Therefore, any modification or improvement made on the basis of the fluorescence polarization principle described in the present invention or the establishment and use of the fluorescence polarization high-throughput screening model of key protease small molecule inhibitors for regulating viral replication in other pathogenic viruses all belong to the protection scope of the present invention. The FITC-S-Biotin substrate used in the present invention is not only limited to the double labeling of FITC and Biotin with the polypeptide sequence described in the application embodiment, but also all Mpro substrate polypeptides containing Mpro conservative cleavage sequence (LQS / A) and other fluorescent molecular markers or synthesized with other amino acid modification technologies, all belong to the protection scope of the present invention. In addition, the new coronavirus Mpro used in the present invention is not limited to the preparation using Escherichia coli prokaryotic expression technology. It is also feasible to prepare Mpro using other eukaryotic expression systems such as yeast cells, CHO cells, insect cells, and plant cells. However, the highly active Mpro should be the structure described in this article, with only one formylmethionine remaining at the amino end or it being a free amino end, and the polyhistidine tag at the carboxyl end is optional, which has little effect on the biological activity of Mpro. This construction strategy of Mpro also falls within the scope of protection of the present invention. SEQUENCE LISTING <110> Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences <120> A method and screening model for screening small molecule inhibitors of the main protease of the new coronavirus <130> CP121020635C <160> 2 <170> PatentIn version 3.3 <210> 1 <211> 930 <212> DNA <213> Artificial sequence <400> 1 catatgagtg gctttcgtaa aatggccttt ccgagcggca aagttgaagg ttgtatggtg 60 caggtgacct gcggtaccac caccctgaat ggtctgtggc tggatgatgt ggtttattgc 120 ccgcgtcatg tgatttgtac cagtgaagat atgctgaatc cgaattatga agatctgctg 180 attcgcaaaa gcaatcataa ttttctggtg caggccggca atgttcagct gcgcgtgatt 240 ggccatagta tgcagaattg cgttctgaaa ctgaaagtgg ataccgcaaa tccgaaaacc 300 ccgaaatata aatttgttcg cattcagccg ggtcagacct ttagcgtgct ggcatgttat 360 aatggtagtc cgagcggtgt gtatcagtgc gcaatgcgtc cgaattttac cattaagggc 420 agttttctga atggtagctg cggcagcgtt ggttttaata ttgattatga ttgcgtgagt 480 ttctgctata tgcatcacat ggaactgccg accggtgtgc atgcaggcac cgatctggaa 540 ggtaattttt atggcccgtt tgtggatcgc cagaccgcac aggcagccgg taccgatacc 600 accattaccg ttaatgttct ggcatggctg tatgcagccg ttattaatgg tgaccgttgg 660 tttctgaatc gttttaccac caccttaaat gattttaatc tggttgccat gaagtataat 720 tacgaaccgc tgacccagga tcatgtggat attctgggcc cgctgagtgc ccagaccggt 780 attgcagttc tggatatgtg tgcaagcctg aaagaactgc tgcagaatgg tatgaatggt 840 cgtaccattc tgggtagtgc actgctggaa gatgaattca ctccgtttga tgttgtgcgc 900 cagtgtagcg gtgtgacctt tcagctcgag 930 <210> 2 <211> 315 <212> PRT <213> Artificial Sequence <400> 2 Met Ser Gly Phe Arg Lys Met Ala Phe Pro Ser Gly Lys Val Glu Gly 1 5 10 15 Cys Met Val Gln Val Thr Cys Gly Thr Thr Thr Leu Asn Gly Leu Trp 20 25 30 Leu Asp Asp Val Val Tyr Cys Pro Arg His Val Ile Cys Thr Ser Glu 35 40 45 Asp Met Leu Asn Pro Asn Tyr Glu Asp Leu Leu Ile Arg Lys Ser Asn 50 55 60 His Asn Phe Leu Val Gln Ala Gly Asn Val Gln Leu Arg Val Ile Gly 65 70 75 80 His Ser Met Gln Asn Cys Val Leu Lys Leu Lys Val Asp Thr Ala Asn 85 90 95 Pro Lys Thr Pro Lys Tyr Lys Phe Val Arg Ile Gln Pro Gly Gln Thr 100 105 110 Phe Ser Val Leu Ala Cys Tyr Asn Gly Ser Pro Ser Gly Val Tyr Gln 115 120 125 Cys Ala Met Arg Pro Asn Phe Thr Ile Lys Gly Ser Phe Leu Asn Gly 130 135 140 Ser Cys Gly Ser Val Gly Phe Asn Ile Asp Tyr Asp Cys Val Ser Phe 145 150 155 160 Cys Tyr Met His His Met Glu Leu Pro Thr Gly Val His Ala Gly Thr 165 170 175 Asp Leu Glu Gly Asn Phe Tyr Gly Pro Phe Val Asp Arg Gln Thr Ala 180 185 190 Gln Ala Ala Gly Thr Asp Thr Thr Ile Thr Val Asn Val Leu Ala Trp 195 200 205 Leu Tyr Ala Ala Val Ile Asn Gly Asp Arg Trp Phe Leu Asn Arg Phe 210 215 220 Thr Thr Thr Leu Asn Asp Phe Asn Leu Val Ala Met Lys Tyr Asn Tyr 225 230 235 240 Glu Pro Leu Thr Gln Asp His Val Asp Ile Leu Gly Pro Leu Ser Ala 245 250 255 Gln Thr Gly Ile Ala Val Leu Asp Met Cys Ala Ser Leu Lys Glu Leu 260 265 270 Leu Gln Asn Gly Met Asn Gly Arg Thr Ile Leu Gly Ser Ala Leu Leu 275 280 285 Glu Asp Glu Phe Thr Pro Phe Asp Val Val Arg Gln Cys Ser Gly Val 290 295 300 Thr Phe Gln Leu Glu His His His His His His 305 310 315
Claims
1. A method for screening small molecule inhibitors of the main protease (Mpro) of the new coronavirus, the method comprising the following steps: (1) Preparation of highly active Mpro recombinant protein by prokaryotic expression in Escherichia coli; (2) Add the compound to be screened and incubate with the Mpro recombinant protein; In step (2), a solution of Mpro recombinant protein with a concentration of 100 to 2000 nM and a compound to be screened with a concentration of 1 to 5 mM are mixed in proportion and incubated together at room temperature for 20 to 60 min; (3) using fluorescein isothiocyanate (FITC) and FITC-Substrate-Biotin polypeptide labeled with Biotin as Mpro hydrolysis substrates, and incubating at room temperature for 5 to 60 minutes; the FITC-Substrate-Biotin polypeptide labeled with Biotin is FITC-AVLQSGFRKK-Biotin; In step (3), the concentration of FITC-Substrate-Biotin is 20 to 100 nM, and the volume of the added FITC-Substrate-Biotin solution is 1 / 2 to 1 / 1 (v / v) of the system in step (2); after adding FITC-Substrate-Biotin, incubate at room temperature for 5 to 40 min; (4) Terminate the hydrolysis reaction with avidin, incubate at room temperature for 1 to 30 min, and detect the mP value with a multifunctional microplate reader; In step (4), the concentration of avidin is 10 to 500 nM, and the volume of the avidin solution added is 1 / 6 to 1 / 1 (v / v) of the system in step (2); after adding avidin, incubate at room temperature for 1 to 10 min, and detect the mP value with a multifunctional microplate reader; (5) Draw the inhibition curve of the target compound and calculate the IC of the target compound against the main protease of the new coronavirus 50 value; The amino acid sequence of the main protease of the new coronavirus is shown in SEQ ID NO.
2.
2. The method according to claim 1, characterized in that: In step (2): a 400 nM Mpro recombinant protein solution was mixed with a 3 mM compound to be screened at a ratio of 1:29 (v / v), and the mixture was incubated at room temperature for 40 min.
3. The method according to claim 1, characterized in that In step (3): the concentration of FITC-Substrate-Biotin is 60 nM, and the volume of the added FITC-Substrate-Biotin solution is 2 / 3 (v / v) of the system in step (2); after adding FITC-Substrate-Biotin, incubate at room temperature for 20 min.
4. The method according to claim 1, characterized in that: In step (4): the concentration of avidin is 300 nM, and the volume of the avidin solution added is 1 / 3 (v / v) of the system in step (2); after adding avidin, incubate at room temperature for 5 min, and detect the mP value with a multifunctional microplate reader.
5. The method according to claim 1, characterized in that The method for preparing highly active Mpro recombinant protein by the E. coli prokaryotic expression method described in step (1) is: ① Connect the Mpro gene fragment with the nucleotide sequence shown in SEQ ID NO.1 to the pET-21a(+) expression vector to construct the recombinant plasmid Mpro-pET-21a; ② Then transform the recombinant plasmid into E. coli Mpro was soluble expressed in Rosetta (DE3) competent cells, and the SARS-CoV-2 Mpro recombinant protein was isolated and purified using a HisTrap affinity chromatography column.
6. The method according to any one of claims 1 to 5, characterized in that: In the step of drawing the inhibition curve of the target compound in step (5), the calculation formula of the inhibition rate is as follows: Target compound inhibition rate (%) = × 100%.
7. A fluorescence polarization screening kit for screening small molecule inhibitors of the main protease of the new coronavirus, the kit comprising: (1) Detecting an effective amount of the novel coronavirus Mpro recombinant protein, the fluorescent probe FITC-Substrate-Biotin, and avidin; the amino acid sequence of the novel coronavirus main protease is shown in SEQ ID NO.2; the fluorescent probe FITC-Substrate-Biotin is FITC-AVLQSGFRKK-Biotin; (2) Necessary solvents and reagents.
8. Use of the fluorescence polarization screening kit for screening small molecule inhibitors of the main protease of the new coronavirus as described in claim 7 in screening small molecule inhibitors of the main protease of the new coronavirus.
